Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

BACKGROUND: An increasing number of studies is now devoted to immunotherapy of cancer. We evaluated the clinical benefit of hepcortespenlisimut-L (Hepko-V5 [formerly known as V5])—an oral therapeutic vaccine designated by the United States Food and Drug Administration (FDA) as an orphan drug for tre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hepatocell Carcinoma
Glavni autori: Tarakanovskaya, Marina G, Chinburen, Jigjidsuren, Batchuluun, Purev, Munkhzaya, Chogsom, Purevsuren, Genden, Dandii, Dorjiin, Hulan, Tsogkhuu, Oyungerel, Dandii, Kutsyna, Galyna A, Reid, Alan A, Borisova, Vika, Bain, Allen I, Jirathitikal, Vichai, Bourinbaiar, Aldar S
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2017
Teme:
Clinical Trial Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5396941/
https://ncbi.nlm.nih.gov/pubmed/28443252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S122507
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items